Guangzhou Vitron

Vigene Biosciences (often referred to in China as Guangzhou Vitron) is a leading provider of viral vector development and manufacturing services for the gene therapy industry. The company specializes in the production of high-quality adeno-associated virus (AAV), lentivirus, and adenovirus vectors, supporting projects from basic research through to clinical trials. In 2021, Vigene was acquired by Charles River Laboratories to serve as a cornerstone of its cell and gene therapy CDMO portfolio. The company is recognized for its extensive library of off-the-shelf viral plasmids and its proprietary technologies for high-titer vector packaging and purification.